FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969131430> ?p ?o ?g. }

• W1969131430 endingPage "1262" @default.
• W1969131430 startingPage "1251" @default.
• W1969131430 abstract "The serotonin1A receptor partial agonist, buspirone, also displays antagonist properties at D2 receptors and is metabolized to the α2-adrenergic receptor antagonist, 1-(2-pyrimidinyl-piperazine). Herein, we examined mechanisms underlying the influence of buspirone alone, and in association with the serotonin reuptake inhibitor, fluoxetine, upon extracellular levels of serotonin, dopamine and noradrenaline simultaneously quantified in the frontal cortex of freely moving rats. Buspirone (0.01–2.5 mg/kg, s.c.) dose-dependently decreased dialysate levels of serotonin (−50%), and increased those of dopamine (+100%) and noradrenaline (+140%). The reduction by buspirone of serotonin levels was abolished by the serotonin1A receptor antagonist, WAY 100,635 (0.16), which did not, however, modify its influence upon dopamine and noradrenaline. In contrast to buspirone, the serotonin reuptake inhibitor, fluoxetine (10.0), increased frontocortical levels of serotonin (+120%), dopamine (+55%) and noradrenaline (+90%). Buspirone dose-dependently (0.01–2.5) decreased the induction by fluoxetine of serotonin levels yet potentiated (three-fold) its elevation of dopamine and noradrenaline levels. The serotonin1A agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (0.16), mimicked the action of buspirone in reducing resting levels of serotonin (−60%) and in enhancing those of dopamine (+135%) and noradrenaline (+165%). Like buspirone, it attenuated the influence of fluoxetine upon serotonin levels, yet facilitated its influence upon dopamine and noradrenaline levels. In contrast, WAY 100,635 selectively potentiated the increase in levels of serotonin (two-fold) versus dopamine and noradrenaline elicited by fluoxetine. Further, WAY 100,635 abolished the inhibitory influence of buspirone upon fluoxetine-induced serotonin release, but only partly interfered with its potentiation of fluoxetine-induced increases in dopamine and noradrenaline levels. The D2/D3 receptor antagonist, raclopride (0.16), increased basal dopamine (+60%) levels but little influenced those of serotonin and noradrenaline, and failed to modify the action of fluoxetine. The α2-adrenergic receptor antagonist, 1-(2-pyrimidinyl-piperazine) (2.5), which did not modify resting levels of serotonin, markedly increased those of dopamine (+90%) and noradrenaline (+190%) and potentiated (two-fold) the increases in dialysate levels of dopamine, noradrenaline and serotonin provoked by fluoxetine. Further, the α2-adrenergic receptor agonist, S18616, attenuated the enhancement by buspirone of the fluoxetine-induced increase in levels of dopamine and noradrenaline. In conclusion, the inhibitory influence of buspirone upon resting and fluoxetine-stimulated serotonin levels reflects its agonist properties at serotonin1A autoreceptors. The facilitatory influence of buspirone upon resting and fluoxetine-stimulated dopamine and noradrenaline levels may also involve its serotonin1A properties. However, its principal mechanism of action in this respect is probably the α2-adrenergic antagonist properties of its metabolite, 1-(2-pyrimidinyl-piperazine). The present observations are of significance to experimental and clinical studies of the influence of buspirone upon depressive states, alone and in association with antidepressant agents." @default.
• W1969131430 created "2016-06-24" @default.
• W1969131430 creator A5015680710 @default.
• W1969131430 creator A5039339834 @default.
• W1969131430 creator A5041494494 @default.
• W1969131430 creator A5070915452 @default.
• W1969131430 creator A5083841715 @default.
• W1969131430 date "1999-08-01" @default.
• W1969131430 modified "2023-10-12" @default.
• W1969131430 title "Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenergic receptors underlie its actions" @default.
• W1969131430 cites W1564435889 @default.
• W1969131430 cites W1572495684 @default.
• W1969131430 cites W1612254223 @default.
• W1969131430 cites W1622773602 @default.
• W1969131430 cites W1674052906 @default.
• W1969131430 cites W173109810 @default.
• W1969131430 cites W179800603 @default.
• W1969131430 cites W1965641144 @default.
• W1969131430 cites W1965771612 @default.
• W1969131430 cites W1968633470 @default.
• W1969131430 cites W1970174017 @default.
• W1969131430 cites W1971395727 @default.
• W1969131430 cites W1971851906 @default.
• W1969131430 cites W1972324473 @default.
• W1969131430 cites W1979214750 @default.
• W1969131430 cites W1985296235 @default.
• W1969131430 cites W1985405824 @default.
• W1969131430 cites W1986891236 @default.
• W1969131430 cites W1987680642 @default.
• W1969131430 cites W1992295593 @default.
• W1969131430 cites W1994702289 @default.
• W1969131430 cites W1994808302 @default.
• W1969131430 cites W1995461188 @default.
• W1969131430 cites W1997880525 @default.
• W1969131430 cites W1998088135 @default.
• W1969131430 cites W1999490123 @default.
• W1969131430 cites W2002671738 @default.
• W1969131430 cites W2006490359 @default.
• W1969131430 cites W2007046516 @default.
• W1969131430 cites W2010221886 @default.
• W1969131430 cites W2010942461 @default.
• W1969131430 cites W2013029536 @default.
• W1969131430 cites W2013750906 @default.
• W1969131430 cites W2014996020 @default.
• W1969131430 cites W2015374273 @default.
• W1969131430 cites W2017826185 @default.
• W1969131430 cites W2024702295 @default.
• W1969131430 cites W2027631045 @default.
• W1969131430 cites W2029049578 @default.
• W1969131430 cites W2029159812 @default.
• W1969131430 cites W2031088014 @default.
• W1969131430 cites W2034867088 @default.
• W1969131430 cites W2035632600 @default.
• W1969131430 cites W2035871206 @default.
• W1969131430 cites W2038004358 @default.
• W1969131430 cites W203807811 @default.
• W1969131430 cites W2045738697 @default.
• W1969131430 cites W2049691147 @default.
• W1969131430 cites W2052001699 @default.
• W1969131430 cites W2052545597 @default.
• W1969131430 cites W2053744108 @default.
• W1969131430 cites W2057346541 @default.
• W1969131430 cites W2058396154 @default.
• W1969131430 cites W2058711144 @default.
• W1969131430 cites W2060259870 @default.
• W1969131430 cites W2060902782 @default.
• W1969131430 cites W2061090773 @default.
• W1969131430 cites W2062254322 @default.
• W1969131430 cites W2062534788 @default.
• W1969131430 cites W2067883239 @default.
• W1969131430 cites W2069296995 @default.
• W1969131430 cites W2069629218 @default.
• W1969131430 cites W2078193026 @default.
• W1969131430 cites W2080431464 @default.
• W1969131430 cites W2082857343 @default.
• W1969131430 cites W2083991574 @default.
• W1969131430 cites W2086370837 @default.
• W1969131430 cites W2090252372 @default.
• W1969131430 cites W2092052553 @default.
• W1969131430 cites W2092377028 @default.
• W1969131430 cites W2092948253 @default.
• W1969131430 cites W2106405415 @default.
• W1969131430 cites W2129083538 @default.
• W1969131430 cites W2130835333 @default.
• W1969131430 cites W2141880924 @default.
• W1969131430 cites W2153317499 @default.
• W1969131430 cites W2155132989 @default.
• W1969131430 cites W2161618882 @default.
• W1969131430 cites W2320247467 @default.
• W1969131430 cites W2321617757 @default.
• W1969131430 cites W2332543303 @default.
• W1969131430 cites W2406356691 @default.
• W1969131430 cites W2953145308 @default.
• W1969131430 cites W4244781478 @default.
• W1969131430 doi "https://doi.org/10.1016/s0306-4522(99)00211-0" @default.
• W1969131430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10501449" @default.
• W1969131430 hasPublicationYear "1999" @default.
• W1969131430 type Work @default.

• next